Avacta to Present Updated Phase 1a Data for FAP-Targeted Doxorubicin Conjugate AVA6000 at ESMO 2025
核心洞察
Avacta Therapeutics (搜索) will present updated Phase 1a trial data for AVA6000, a peptide drug conjugate targeting FAP-positive solid tumors (搜索), at the 2025 ESMO Congress in Berlin.
AVA6000 consists of doxorubicin conjugated with a peptide moiety that is specifically cleaved by Fibroblast Activation Protein (搜索) in the tumor microenvironment.
The company completed Phase 1a dose escalation enrollment in late 2024 and continues patient enrollment in multiple Phase 1b dose expansion cohorts.
Avacta Therapeutics (搜索) will present updated clinical data for its novel peptide drug conjugate AVA6000 at the 2025 European Society for Medical Oncology (ESMO) Congress, scheduled for October 17-21 in Berlin, Germany. The presentation will feature the most recent data analysis from the Phase 1a trial of FAP-Dox (搜索) (AVA6000) in patients with Fibroblast Activation Protein (搜索) (FAP (搜索))-positive solid tumors (搜索).
Novel Targeting Mechanism
AVA6000 represents an innovative approach to targeted cancer therapy, consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP (搜索) in the tumor microenvironment. This design allows for selective drug release within the tumor, potentially improving therapeutic efficacy while reducing systemic toxicity associated with conventional doxorubicin administration.
Clinical Development Progress
Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, marking a significant milestone in the drug's development. Patient enrollment continues in multiple dose expansion cohorts of a Phase 1b study, indicating the company's commitment to thoroughly evaluating the therapeutic potential of AVA6000 across different patient populations and dosing regimens.
ESMO Presentation Details
The poster presentation, titled "A Phase I trial of FAP-Dox (搜索) (AVA6000), a Fibroblast Activation Protein (搜索) (FAP (搜索))-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors (搜索)," will be delivered by William D. Tap during the Developmental Therapeutics session. The presentation is scheduled for October 17 from 19:40 to 20:00 at the Berlin Auditorium - Hub 27, with abstract presentation number 964P.
Following the ESMO presentation, Avacta plans to hold an investor event to discuss the clinical findings and their implications for the continued development of AVA6000. The company has indicated that further details regarding this investor event will be provided closer to the conference date.